MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis

@article{Smith2021MDMAAssistedPF,
  title={MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis},
  author={Kimberly W Smith and Dakota J Sicignano and Adrian V. Hern{\'a}ndez and C Michael White},
  journal={The Journal of Clinical Pharmacology},
  year={2021},
  volume={62}
}
This article discusses current literature on the use of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA‐assisted psychotherapy, patients are subjected to 2 or 3 multihour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to… 

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares,

Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model

The current standard of care in most uses of psychedelic medicines for the treatment of psychiatric indications includes the provision of a supportive therapeutic context before, during, and after

MDMA for the treatment of misophonia, a proposal

Misophonia is a disorder characterized by negative physical and emotional reactions to certain trigger sounds, such as chewing food. Up to 50% of population samples endorse some symptoms of

MDMA for the Treatment of Negative Symptoms in Schizophrenia

This review provides a rationale for the use of MDMA in the treatment of negative symptoms by reviewing the literature on negative symptoms, their treatment, MDMA, and MDMA-assisted therapy and concludes with considerations regarding safety and possible mechanisms of action.

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

Evidence-informed tips for PC clinicians synthesized through consultation with interdisciplinary and international leading experts in the field are offered to familiarize clinicians and teams with PAT.

MDMA and Their Analogs as Therapeutics for Mental Disorder and Response Predictor.

Provided herein are MDMA and their analogs for the potential psychotherapy-assisted treatment of alcohol use disorder (AUD), post-traumatic stress disorder (PTSD), and a method of predicting dosing

Sober sitter or coconsumer? Psychedelics, online forums and preferences for interpersonal interactions

Abstract Contemporary clinical research into the psychotherapeutic administration of psychedelics has primarily emphasized the importance of therapeutic interpersonal interactions to assist clients

Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with ΔG Calculations, Induced Fit Docking and Monte Carlo Simulations

A structure-based mechanistic model of MDMA occupation and translocation across both binding sites, applying ensemble binding space analyses, electrostatic complementarity, and Monte Carlo energy perturbation theory is proposed to provide a framework for future virtual screening studies and pharmaceutical design and to develop hSERT allosteric compounds with a unique psychoactive MDMA-like profile.

Coming clean: Saying ‘know’ to drugs – Part II

References

SHOWING 1-10 OF 23 REFERENCES

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Comparing data used for the approval of paroxetine and sertraline and pooled data from Phase 2 studies, MAPS demonstrated that MDMA-assisted psychotherapy constitutes a substantial improvement over available pharmacotherapies in terms of safety and efficacy.

Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin

A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text and the evidence for ketamine as a stand-alone treatment for comorbid PTSD and depression was ranked “very low”.

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials

PTSD symptoms were reduced 1 to 2 months after MDMA-assisted psychotherapy, and symptom improvement continued at least 12 months post-treatment, and Phase 3 trials are investigating this novel treatment approach in a larger sample of participants with chronic PTSD.

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial

The findings of this pilot dose response trial support previous investigations of MDMA-assisted psychotherapy as an innovative, efficacious treatment for posttraumatic stress disorder.

3,4-Methylenedioxymethamphetamine’s (MDMA’s) Impact on Posttraumatic Stress Disorder

  • C. White
  • Psychology
    The Annals of pharmacotherapy
  • 2014
Therapy with MDMA-assisted psychotherapy is promising, with reductions in PTSD rating scale scores, although 2 of 3 trials did not show significant results, and all three had methodological limitations.

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.

MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder

It was found that low doses of MDMA were both psychologically and physiologically safe for all the subjects and future studies in larger samples and using larger doses are needed in order to further clarify the safety and efficacy of MDMA in the clinical setting in subjects with PTSD.

Fluoxetine in posttraumatic stress disorder.

Fluoxetine is an effective pharmacotherapeutic agent for treating PTSD and its associated features, particularly in patients without chronic treatment histories, and non-VA patients responded much better than VA patients.

Summary of the clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults.

  • Psychology, Medicine
    The American psychologist
  • 2019
The GDP conditionally recommends the use of brief eclectic psychotherapy, eye movement desensitization and reprocessing (EMDR), and narrative exposure therapy (NET), and concluded that future systematic reviews that incorporated new studies could change the recommendations for EMDR and NET from conditional to strong.

Open Prospective Trial of Fluoxetine for Posttraumatic Stress Disorder

It is suggested that fluoxetine is effective in reducing reexperiencing, avoidance, and hyperarousal symptoms of PTSD, and this improvement is independent of comorbid panic disorder, and the findings should be confirmed by double-blind, placebo-controlled studies.